A Phase 4 interventional study of Ixekizumab and Guselkumab in Plaque Psoriasis, sponsored by Eli Lilly and Company. Completed at 124 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-28.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.
Among the 22 studies testing ixekizumab in Psoriasis, this one is the 5th largest by enrollment, is the only one that started in 2018, is one of 6 in phase 4, and was the 15th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
Singapore General Hospital · Sites in Singapore
Ages 22–90
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ages 70+
By country, each count listing its studies:
ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,027 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 156 across the 22 interventional studies. Of the 17 that completed or were terminated, 16 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
36 studies in Psoriasis by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 35 finished, 28 (80%) have results posted.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 7th largest by enrollment, is one of 6 that started in 2018, is one of 3 in phase 4, and was the 25th registered.
Eli Lilly and Company’s Psoriasis studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing ixekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 36 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A starting dose of 160 milligram (mg) of ixekizumab was given as 2 subcutaneous (SC) injections at Week 0. During the Induction Period, ixekizumab 80 mg was given every 2 weeks (Q2W) at Weeks 2, 4, 6, 8, 10, and 12. During the Extension Period, ixekizumab 80 mg was given as 1 SC injection (Q4W) every 4 weeks at Weeks 16 and 20. The Post Treatment Follow Up Period was for safety monitoring following the last treatment period.
Drug: Ixekizumab
During the Induction Period, guselkumab 100 mg was given as 1 SC injection at Weeks 0, 4 and 12. 1 placebo injection (to maintain the blind) was given at Weeks 0, 2, 6, 8, and 10. During the Extension Period, guselkumab 100 mg was given at Week 20. 1 placebo injection (to maintain the blind) was given at Week 16. The Post Treatment Follow Up Period was for safety monitoring following the last treatment period.
Drug: Guselkumab · Drug: Placebo
Administered SC
Also known as: LY2439821
Administered SC
Administered SC
Percentage of Participants Achieving 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI 100)
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.
Time frame: Week 12
Percentage of Participants Achieving PASI 75
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in the PASI scores compared to baseline.
Time frame: Week 2
Percentage of Participants Achieving PASI 90
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 90 were defined as having an improvement of at least 90% in the PASI scores compared to baseline.
Time frame: Week 4
Percentage of Participants Achieving PASI 100
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.
Time frame: Week 4
Percentage of Participants Achieving PASI 90
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 90 were defined as having an improvement of at least 90% in the PASI scores compared to baseline.
Time frame: Week 8
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) (0)
The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0) response was defined as a post-baseline sPGA score of 0.
Time frame: Week 12
Percentage of Participants Achieving PASI 50
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 50 were defined as having an improvement of at least 50% in the PASI scores compared to baseline.
Time frame: Week 1
Percentage of Participants Achieving PASI 100
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.
Time frame: Week 8
Percentage of Participants Achieving PASI 100
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.
Time frame: Week 24
| Milestone | Ixekizumab | Guselkumab |
|---|---|---|
| Started | 520 | 507 |
| Received at least one dose of study drug | 519 | 506 |
| Completed | 465 | 459 |
| Not completed | 55 | 48 |
| Withdrew: Screen failure | 1 | 1 |
| Withdrew: Adverse event | 15 | 8 |
| Withdrew: Protocol violation | 3 | 8 |
| Withdrew: Withdrawal by subject | 17 | 9 |
| Withdrew: Lack of efficacy | 2 | 3 |
| Withdrew: Pregnancy | 1 | 2 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Lost to follow-up | 14 | 13 |
| Withdrew: Sponsor decision | 0 | 1 |
| Withdrew: Alkaline phosphatase (alp) level reached | 0 | 1 |
| Withdrew: Noncompliant to protocol procedures | 1 | 2 |
| Milestone | Ixekizumab | Guselkumab |
|---|---|---|
| Started | 465 | 456 |
| Completed | 406 | 399 |
| Not completed | 59 | 57 |
| Withdrew: Withdrawal by subject | 22 | 12 |
| Withdrew: Lack of efficacy | 8 | 19 |
| Withdrew: Physician decision | 4 | 3 |
| Withdrew: Did not wish to return to study | 3 | 2 |
| Withdrew: Discontinued trt and completed follow up | 14 | 8 |
| Withdrew: Not compliant to protocol procedures | 8 | 11 |
| Withdrew: Sponsor decision | 0 | 1 |
| Withdrew: Repeat infections | 0 | 1 |
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.
| percentage of participants | Ixekizumab | Guselkumab |
|---|---|---|
| Percentage of Participants Achieving 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI 100) | 41.3 (37.1 to 45.6) | 24.9 (21.1 to 28.6) |
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in the PASI scores compared to baseline.
| percentage of participants | Ixekizumab | Guselkumab |
|---|---|---|
| Percentage of Participants Achieving PASI 75 | 22.9 (19.3 to 26.5) | 5.1 (3.2 to 7.0) |
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 90 were defined as having an improvement of at least 90% in the PASI scores compared to baseline.
| percentage of participants | Ixekizumab | Guselkumab |
|---|---|---|
| Percentage of Participants Achieving PASI 90 | 21.0 (17.5 to 24.5) | 7.9 (5.5 to 10.2) |
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.
| percentage of participants | Ixekizumab | Guselkumab |
|---|---|---|
| Percentage of Participants Achieving PASI 100 | 6.7 (4.6 to 8.9) | 1.4 (0.4 to 2.4) |
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 90 were defined as having an improvement of at least 90% in the PASI scores compared to baseline.
| percentage of participants | Ixekizumab | Guselkumab |
|---|---|---|
| Percentage of Participants Achieving PASI 90 | 58.5 (54.2 to 62.7) | 35.9 (31.7 to 40.1) |
The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5). An sPGA (0) response was defined as a post-baseline sPGA score of 0.
| percentage of participants | Ixekizumab | Guselkumab |
|---|---|---|
| Percentage of Participants Achieving Static Physician Global Assessment (sPGA) (0) | 41.9 (37.7 to 46.2) | 25.2 (21.5 to 29.0) |
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 50 were defined as having an improvement of at least 50% in the PASI scores compared to baseline.
| percentage of participants | Ixekizumab | Guselkumab |
|---|---|---|
| Percentage of Participants Achieving PASI 50 | 27.5 (23.7 to 31.3) | 9.3 (6.7 to 11.8) |
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.
| percentage of participants | Ixekizumab | Guselkumab |
|---|---|---|
| Percentage of Participants Achieving PASI 100 | 29.6 (25.7 to 33.5) | 13.6 (10.6 to 16.6) |
The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.
| percentage of participants | Ixekizumab | Guselkumab |
|---|---|---|
| Percentage of Participants Achieving PASI 100 | 50.0 (45.7 to 54.3) | 52.3 (47.9 to 56.6) |
Collected over Up to 48 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ixekizumab | 0/519 (0%) | 18/519 (3.5%) | 113/519 (21.8%) |
| Guselkumab | 0/506 (0%) | 16/506 (3.2%) | 73/506 (14.4%) |
| Ixekizumab Post-Treatment Follow Up | 0/465 (0%) | 4/465 (0.9%) | 11/465 (2.4%) |
| Guselkumab Post-Treatment Follow Up | 0/456 (0%) | 4/456 (0.9%) | 9/456 (2%) |
| Event | Ixekizumab | Guselkumab | Ixekizumab Post-Treatment Follow Up | Guselkumab Post-Treatment Follow Up |
|---|---|---|---|---|
| Endometrial cancer stage ivNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/182 | 1/193 | 0/164 | 0/170 |
| Myocardial infarctionCardiac disorders | 1/519 | 2/506 | 0/465 | 0/456 |
| CellulitisInfections and infestations | 0/519 | 2/506 | 0/465 | 0/456 |
| SyncopeNervous system disorders | 2/519 | 0/506 | 0/465 | 0/456 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/337 | 0/313 | 0/301 | 1/286 |
| Ventricular tachycardiaCardiac disorders | 0/519 | 0/506 | 0/465 | 1/456 |
| Joint dislocationInjury, poisoning and procedural complications | 0/519 | 0/506 | 0/465 | 1/456 |
| UreterolithiasisRenal and urinary disorders | 0/519 | 0/506 | 0/465 | 1/456 |
| Colitis ulcerativeGastrointestinal disorders | 0/519 | 0/506 | 1/465 | 0/456 |
| Crohn's diseaseGastrointestinal disorders | 1/519 | 0/506 | 1/465 | 0/456 |
| Event | Ixekizumab | Guselkumab | Ixekizumab Post-Treatment Follow Up | Guselkumab Post-Treatment Follow Up |
|---|---|---|---|---|
| Injection site reactionGeneral disorders | 49/519 | 6/506 | 0/465 | 1/456 |
| Upper respiratory tract infectionInfections and infestations | 40/519 | 41/506 | 6/465 | 6/456 |
| NasopharyngitisInfections and infestations | 34/519 | 27/506 | 5/465 | 2/456 |
All randomized participants.
| Age, Continuous(years) | Ixekizumab | Guselkumab | Total |
|---|---|---|---|
| Mean | 49.0 ± 13.90 | 49.0 ± 14.88 | 49.0 ± 14.39 |
| Sex: Female, Male(Participants) | Ixekizumab | Guselkumab | Total |
|---|---|---|---|
| Female | 182 | 193 | 375 |
| Male | 338 | 314 | 652 |
| Ethnicity (NIH/OMB)(Participants) | Ixekizumab | Guselkumab | Total |
|---|---|---|---|
| Hispanic or Latino | 127 | 120 | 247 |
| Not Hispanic or Latino | 383 | 379 | 762 |
| Unknown or Not Reported | 10 | 8 | 18 |
| Race (NIH/OMB)(Participants) | Ixekizumab | Guselkumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 7 | 6 | 13 |
| Asian | 31 | 35 | 66 |
| Native Hawaiian or Other Pacific Islander | 2 | 2 | 4 |
| Black or African American | 38 | 29 | 67 |
| White | 439 | 431 | 870 |
| More than one race | 2 | 4 | 6 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Ixekizumab | Guselkumab | Total |
|---|---|---|---|
| Canada | 103 | 106 | 209 |
| United States | 417 | 401 | 818 |
Showing the first 100 of 124 sites across 3 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Nov 2018 to primary completion in Jul 2019, 8 months.
Results were first posted in Jul 2020, 1 year after primary completion.
Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 8 months is below that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ixekizumab · Guselkumab